News

Cholesterol-lowering drug aids mitochondria in Parkinson’s models

Probucol, a cholesterol-lowering medication previously used in Western countries, improved motor function and lengthened the lifespan of treated animals in models of Parkinson’s disease, a study found. Identified as a potential Parkinson’s treatment through an artificial intelligence (AI)-based search, probucol was found to promote mitophagy, the cellular pathway that recycles…

Patients with persistent tremor sought for suvecaltamide trial

Parkinson’s disease patients with inadequately controlled tremors are being sought for a Phase 2 clinical trial of suvecaltamide, an oral treatment candidate from Jazz Pharmaceuticals. The Phase 2 trial (NCT05642442), which enrolled its first participant late last year, seeks about 160 adults, ages 40-80, with Parkinson’s who have…

$400K award will go to explore brain-gut connection in Parkinson’s

The U.S. Department of Defense has awarded $400,000 to an Augusta University (AU) neuroscientist to research a possible brain-gut connection in Parkinson’s disease. Danielle Mor, PhD, from the Medical College of Georgia at AU, will use the two-year Early-Investigator Research Award to explore whether Parkinson’s starts in the gut. Specifically,…

Inflammation elevated in brains of newly diagnosed patients

Inflammation in the brain is detectable at the earliest stages of Parkinson’s disease and even before treatment is begun, a new study reports. The findings support the idea that inflammation may be an early driver of Parkinson’s itself, rather than merely a byproduct of the disease’s neurodegeneration, the researchers…

Genetics study in Black, African American people expands

The Black and African American Connections to Parkinson’s Disease (BLAAC PD) study, a research effort to understand the genetic complexities of Parkinson’s disease among traditionally underrepresented people, has now expanded to six clinical sites. A better understanding of genetic variants associated with the neurological condition specific to this…

Resveratrol oral formulation Jotrol shows gains in mouse model

Jotrol, Jupiter Neuroscience’s oral formulation of resveratrol, significantly improved muscle strength, motor coordination, and behavior in a mouse model of Parkinson’s disease, the company reported. “This research demonstrates the neuroprotectant abilities of Jotrol as a potential treatment to prevent onset and progression of PD [Parkinson’s] symptoms,” said Alison…